+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Three cases with pelvic dead space infection after total cystectomy caused by methicillin-resistant Staphylococcus aureus (MRSA)--local injection of vancomycin

Three cases with pelvic dead space infection after total cystectomy caused by methicillin-resistant Staphylococcus aureus (MRSA)--local injection of vancomycin

Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 67(6): 584-588

We recently had three patients with pelvic dead space infection caused by methicillin-resistant Staphylococcus aureus (MRSA) after total cystectomy for urothelial cancer. All were male and aged from 67 to 74 years old. As for underlying diseases, two of them had bladder cancer and one of them had bladder cancer and right ureteral cancer. Total cystectomy and ileal conduit were performed for two patients with bladder cancer, and total cystectomy, nephroureterectomy and ureterocutaneoustomy were performed for a patient with bladder cancer and ureteral cancer. Pelvic dead space infections caused by MRSA appeared after 15-30 days postoperatively. All patients were cured after we locally administered 0.5 g of vancomycin twice a day for 10-11 days from the drains to the pelvic dead spaces. All patients had preoperative antitumor chemotherapy and the postoperative administrations of beta-lactams in common. From these results, we suggest that local administration of vancomycin is effective for the pelvic dead space infection caused by MRSA after total cystectomy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 047779441

Download citation: RISBibTeXText

PMID: 8336013

Related references

Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Journal of Antimicrobial ChemoTherapy 64(2): 364-369, 2009

Vancomycin-impregnated polymethylmethacrylate beads for methicillin-resistant Staphylococcus aureus (MRSA) infection: report of two cases. Journal of Orthopaedic Science 3(3): 163-168, 1998

Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clinical Infectious Diseases 26(5): 1204-1214, 1998

Genesis of Methicillin-Resistant Staphylococcus aureus (Mrsa), How Treatment of Mrsa Infections Has Selected for Vancomycin-Resistant Enterococcus faecium, and the Importance of Antibiotic Management and Infection Control. Clinical Infectious Diseases 26(5): 1204-1214, 1998

In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). International Journal of Antimicrobial Agents 36(1): 69-72, 2010

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Journal of Antimicrobial ChemoTherapy 60(4): 788-794, 2007

A case of empyema after pneumonectomy caused by methicillin-resistant staphylococcus aureus infection treated successfully with local administration with vancomycin. Pneumonologia i Alergologia Polska 67(1-2): 60-64, 1999

Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrobial Agents and ChemoTherapy 53(8): 3447-3452, 2009

Evaluation of the novel artus C. difficile QS-RGQ, VanR QS-RGQ and MRSA/SA QS-RGQ assays for the laboratory diagnosis of Clostridium difficile infection (CDI), and for vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) screening. European Journal of Clinical Microbiology and Infectious Diseases 36(5): 823-829, 2016

State of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) in Extremadura: susceptibility, clonality and role of community-associated MRSA. Revista Espanola de Quimioterapia 27(3): 180-189, 2015

Design and Syntheses of Highly Potent Teixobactin Analogues against Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo. Journal of Medicinal Chemistry 61(5): 2009-2017, 2018

Methicillin-resistant Staphylococcus aureus (MRSA) is increasing in Norway: a time series analysis of reported MRSA and methicillin-sensitive S. aureus cases, 1997-2010. Plos One 8(8): E70499, 2014

Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. American Journal of Transplantation 9 Suppl 4: S41-S49, 2010

Treatment of infection caused by methicillin resistant staphylococcus aureus mrsa. Journal of Tokyo Women's Medical College 62(4): 320-329, 1992

Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin. Antimicrobial Agents and ChemoTherapy 55(5): 2458-2459, 2011